Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas
J. Clin. Invest. Danan Li, et al. 117:346 doi:10.1172/JCI30446 [Go to this article.]

Figure 4
EGFR kinase domain mutation L858R–driven mouse lung adenocarcinoma responds to ch806 treatment. (A) Tet-op-EGFR L858R-IRES-Luciferase/CCSP-rtTA mice were treated with ch806 at 0.5 mg per dose by daily i.p. injection for 4 weeks. MRI showed decreased tumor volume after 2 and 4 weeks of treatment. Data (expressed as mean ± SD) illustrate the tumor regression measured by MRI, and statistical analyses were performed using 2-tailed unpaired Student’s t test. (B) Histopathological analysis shows shrinkage of tumors and marked macrophage infiltration in ch806-treated Tet-op-EGFR L858R-IRES-Luciferase/CCSP-rtTA mice (right 2 panels), when compared with untreated Tet-op-EGFR L858R-IRES-Luciferase/CCSP-rtTA control mice (left 2 panels). Arrows show foci of residual tumors.